5 Implementation

5 Implementation

5.1 Section 7(6) of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires clinical commissioning groups, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this appraisal within 3 months of its date of publication.

5.2 The Welsh Assembly Minister for Health and Social Services has issued directions to the NHS in Wales on implementing NICE technology appraisal guidance. When a NICE technology appraisal recommends the use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 3 months of the guidance being published.

5.3 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has non-small-cell lung cancer, and the doctor responsible for their care thinks that pemetrexed is the right treatment, it should be available for use, in line with NICE's recommendations.

5.4 NHS England and Eli Lilly and Company have agreed a commercial access agreement that makes pemetrexed for continuation maintenance treatment (that is, after pemetrexed and cisplatin induction therapy) available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence. Any enquiries from NHS organisations about the commercial access agreement should be directed to productsupply@lilly.com.

  • National Institute for Health and Care Excellence (NICE)